Woo Kyun Bae1, Jihyun Kwon2, Hyun Woo Lee3, Sang-Cheol Lee4, Eun-Kee Song5, Hyeok Shim6, Keun Ho Ryu7, Jemin Song8, Sungbo Seo8, Yaewon Yang2, Jong-Hyock Park9, Ki Hyeong Lee2,10, Hye Sook Han11,12. 1. Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun-Gun, South Korea. 2. Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, South Korea. 3. Department of Internal Medicine, Ajou University School of Medicine, Suwon, South Korea. 4. Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, South Korea. 5. Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, South Korea. 6. Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, South Korea. 7. Database/Bioinformatics Laboratory, College of Electrical & Computer Engineering, Chungbuk National University, Cheongju, South Korea. 8. Turbosoft Inc., Cheongwon, South Korea. 9. College of Medicine/Graduate School of Health Science Business Convergence, Chungbuk National University, Cheongju, South Korea. 10. Department of Internal Medicine, College of Medicine, Chungbuk National University, Chungdae-ro 1, Seowon-gu, Cheongju, 28644, South Korea. 11. Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, South Korea. sook3529@hanmail.net. 12. Department of Internal Medicine, College of Medicine, Chungbuk National University, Chungdae-ro 1, Seowon-gu, Cheongju, 28644, South Korea. sook3529@hanmail.net.
Abstract
PURPOSE: There is growing interest in integrating electronic patient-reported outcome (PRO) measures into routine oncology practice for symptom monitoring. Here, we evaluated the feasibility and accessibility of electronic PRO measures using a smartphone (PRO-SMART) for cancer patients receiving routine chemotherapy. METHODS: The proposed PRO-SMART application obtains daily personal health record (PHR) data from cancer patients via a smartphone. An analysis report of cumulative PHR data is provided to the clinician in a format suitable for upload to electronic medical records (EMRs). Cancer outpatients who had received at least two cycles of chemotherapy and who were scheduled for two more cycles were enrolled. RESULTS:Between February 2015 and December 2016, 111 patients were screened and 101 of these were included. One-hundred patients used PRO-SMART at least once and were included in the final analysis (90.1% overall accessibility among all screened patients). The number of symptomatic adverse events (AEs) related to chemotherapy recorded in EMRs (mean ± standard deviation [SD]) increased from 0.92 ± 0.80 to 2.26 ± 1.80 (P < 0.001), and grading of AEs increased from 0.81 ± 0.69 to 1.00 ± 0.62 (P = 0.029). After using PRO-SMART, the numeric rating scale for pain (mean ± SD) increased from 0.20 ± 0.72 to 0.99 ± 1.55 (P < 0.001). A patient-reported questionnaire revealed that 64.2% of patients found it useful and 83% found it easy to use. CONCLUSIONS: This study suggests that the proposed PRO-SMART is feasible and accessible for assessment of symptomatic AEs in cancer patients receivingchemotherapy for a prospective randomized trial.
RCT Entities:
PURPOSE: There is growing interest in integrating electronic patient-reported outcome (PRO) measures into routine oncology practice for symptom monitoring. Here, we evaluated the feasibility and accessibility of electronic PRO measures using a smartphone (PRO-SMART) for cancerpatients receiving routine chemotherapy. METHODS: The proposed PRO-SMART application obtains daily personal health record (PHR) data from cancerpatients via a smartphone. An analysis report of cumulative PHR data is provided to the clinician in a format suitable for upload to electronic medical records (EMRs). Cancer outpatients who had received at least two cycles of chemotherapy and who were scheduled for two more cycles were enrolled. RESULTS: Between February 2015 and December 2016, 111 patients were screened and 101 of these were included. One-hundred patients used PRO-SMART at least once and were included in the final analysis (90.1% overall accessibility among all screened patients). The number of symptomatic adverse events (AEs) related to chemotherapy recorded in EMRs (mean ± standard deviation [SD]) increased from 0.92 ± 0.80 to 2.26 ± 1.80 (P < 0.001), and grading of AEs increased from 0.81 ± 0.69 to 1.00 ± 0.62 (P = 0.029). After using PRO-SMART, the numeric rating scale for pain (mean ± SD) increased from 0.20 ± 0.72 to 0.99 ± 1.55 (P < 0.001). A patient-reported questionnaire revealed that 64.2% of patients found it useful and 83% found it easy to use. CONCLUSIONS: This study suggests that the proposed PRO-SMART is feasible and accessible for assessment of symptomatic AEs in cancerpatients receiving chemotherapy for a prospective randomized trial.
Authors: B J Paessens; C von Schilling; K Berger; M Shlaen; C Müller-Thomas; R Bernard; C Peschel; A Ihbe-Heffinger Journal: Ann Oncol Date: 2011-02-22 Impact factor: 32.976
Authors: Thomas M Atkinson; Sean J Ryan; Antonia V Bennett; Angela M Stover; Rebecca M Saracino; Lauren J Rogak; Sarah T Jewell; Konstantina Matsoukas; Yuelin Li; Ethan Basch Journal: Support Care Cancer Date: 2016-06-03 Impact factor: 3.603
Authors: Frank J Penedo; Laura B Oswald; Joshua P Kronenfeld; Sofia F Garcia; David Cella; Betina Yanez Journal: Lancet Oncol Date: 2020-05 Impact factor: 41.316
Authors: Hninyee Win; Samantha Russell; Betsy C Wertheim; Victoria Maizes; Robert Crocker; Audrey J Brooks; Ruben Mesa; Jennifer Huberty; Holly Geyer; Ryan Eckert; Ashley Larsen; Krisstina Gowin Journal: JMIR Form Res Date: 2022-03-31
Authors: Jolie N Haun; Amy C Alman; Christine Melillo; Maisha Standifer; Julie McMahon-Grenz; Marlena Shin; W A Lapcevic; Nitin Patel; A Rani Elwy Journal: JMIR Med Inform Date: 2020-06-26
Authors: Youmin Cho; Yun Jiang; Huiting Zhang; Marcelline Ruth Harris; Yang Gong; Ellen Lavoie Smith Journal: J Med Internet Res Date: 2021-03-12 Impact factor: 5.428
Authors: Anna Maria Hage; Pimrapat Gebert; Friedrich Kühn; Therese Pross; Ulrike Grittner; Maria Margarete Karsten Journal: Int J Environ Res Public Health Date: 2022-07-07 Impact factor: 4.614